| Literature DB >> 33004159 |
Ivan Urits1, Kyle Gress2, Karina Charipova2, Kelly Habib3, David Lee3, Christopher Lee4, Jai Won Jung2, Hisham Kassem5, Elyse Cornett6, Antonella Paladini7, Giustino Varrassi8, Alan D Kaye6, Omar Viswanath9.
Abstract
Chronic pain can be recurrent or constant pain that lasts for longer than 3 months and can result in disability, suffering, and a physical disturbance. Related to the complex nature of chronic pain, treatments have a pharmacological and non-pharmacological approach. Due to the opioid epidemic, alternative therapies have been introduced, and components of the plant Cannabis Sativa, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have gained recent interest as a choice of treatment. The exact mechanism for CBD is currently unknown, but unlike the CBD's psychoactive counterpart, THC, the side effects of CBD itself have been shown to be overall much more benign. The current pharmaceutical products for the treatment of chronic pain are known as nabiximols, and they contain a ratio of THC combined with CBD, which has been promising. This review focuses on the treatment efficacy of CBD, THC: CBD-based treatments for chronic pain and adverse events with each.Entities:
Keywords: cannabidiol; chronic pain; nabiximols
Mesh：
Substances：
Year: 2020 PMID： 33004159 DOI： 10.1016/j.bpa.2020.06.004
Source DB: PubMed Journal: Best Pract Res Clin Anaesthesiol ISSN： 1521-6896